Aclidinium/formoterol
Aclidinium/formoterol (trade names Duaklir and Brimica) is a combination drug for inhalation, used in the management of chronic obstructive pulmonary disease (COPD). It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β2 agonist.[1]
Combination of | |
---|---|
Aclidinium bromide | Long-acting muscarinic antagonist |
Formoterol | Long-acting β2 agonist |
Clinical data | |
Trade names | Brimica Genuair, Duaklir Genuair |
AHFS/Drugs.com | UK Drug Information |
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
References
- "Duaklir Genuair". European Medicines Agency. 2014-12-05. Retrieved 2015-06-01.
Adrenergics, inhalants |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Glucocorticoids | |||||||||
Anticholinergics/ muscarinic antagonist | |||||||||
Mast cell stabilizers | |||||||||
Xanthines | |||||||||
Eicosanoid inhibition |
| ||||||||
Others/unknown | |||||||||
Combination products | |||||||||
|
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.